Clinical Trial Update: Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of toripalimab with or without celecoxib in mismatch repair-deficient/MSI-H colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer with Microsatellite Instability-high
• Colorectal Cancer with Mismatch Repair Deficiency

Drugs mentioned

• Celecoxib (Celecoxib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Status: RECRUITING